Fudan University

This study compares three ways of giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed with surgery. The goal is to see which timing—before surgery, after surgery, or both—works best to keep the cancer from coming b…

This study tests two drugs (imlunestrant and abemaciclib) given before surgery to shrink tumors in people with a common type of breast cancer (ER-positive, HER2-negative). About 189 women aged 18-75 will take these pills for a few weeks, and doctors will check how well the tumor …

This study tests whether a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than another immunotherapy plus chemotherapy for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. About 104 adults will…

This study tests the best order of two powerful targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) in people with HER2-low, TROP2-high metastatic breast cancer. About 216 participants will be randomly assigned to start with one drug and switch to the other upon pro…

This study looks at whether adding diabetes medication to standard chemotherapy can help people with advanced pancreatic cancer and diabetes live longer. About 210 adults with metastatic pancreatic cancer and diabetes will receive either chemotherapy alone or chemotherapy plus ac…

This phase 3 trial tests whether adding famitinib to SHR-A1811 works better than SHR-A1811 alone for people with advanced HR+/HER2- breast cancer that no longer responds to CDK4/6 inhibitors. About 248 women aged 18-70 will take part. The main goal is to see how long the cancer s…

This study tests a new drug combination for people with advanced soft tissue sarcoma that has not responded to earlier treatments. The treatment includes an immunotherapy drug (epalrotokewali) plus chemotherapy, a targeted therapy, and radiation. The goal is to see if this combin…

This study tests different drug combinations before surgery for people with locally advanced colorectal cancer. The treatment is chosen based on the tumor's genetic and molecular features. The goal is to see if personalized neoadjuvant therapy can improve complete response rates …

This study tests three treatment plans for people with a specific type of colorectal cancer (MSI-H/dMMR) that has spread locally but not to distant organs. The treatments use immunotherapy drugs (nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus radiation) before any …

This study tests whether a single, low dose of radiation to all visible tumors can help immunotherapy drugs work again in people with advanced esophageal cancer that stopped responding to initial treatment. About 32 adults will receive one round of low-dose radiation and then con…

This study tests if a targeted drug (CDK4/6 inhibitor) combined with hormone therapy can replace chemotherapy for women with small but high-risk ER-positive breast cancer. About 2,288 participants will either receive the new drug combo or standard chemo plus hormones. The goal is…

This study tests a combination of two drugs (sacituzumab tirumotecan and furmonertinib) in 45 adults with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to initial treatment. The goal is to see if the combination can shrink tumors…

This study tests a personalized approach using MRI scans to guide chemotherapy and radiation, plus immunotherapy, for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this tailored treatment can help keep the cancer from growing for …

This study tests a combination of two drugs, envafolimab and lenvatinib, as the first treatment for people with a type of kidney cancer (clear cell renal cell carcinoma) that has spread to the liver. The goal is to see if the combination can shrink liver tumors and help patients …

This study tests a new drug, QLC5513, given alone or with another drug (QL1706) in people with advanced triple-negative breast cancer that has worsened after at least one prior treatment. The goal is to see if the treatment can shrink tumors or slow the disease. About 60 women wi…

This study tests whether adding the drug fluzoparib to standard treatment can help prevent breast cancer from coming back in women with early-stage breast cancer who have specific gene changes (HRR mutations). About 334 women will be randomly assigned to receive either fluzoparib…

This study tests whether adding bevacizumab to trastuzumab deruxtecan (T-DXd) works better than T-DXd alone for people with HER2-low breast cancer that has spread to the brain. About 140 adults whose cancer has not been controlled by prior treatments will be randomly assigned to …

This phase II trial tests whether combining multi-mode thermal therapy (using heat to target tumors) with immunotherapy can help control HER2-negative breast cancer that has spread to the liver. The study will enroll 30 women who have already tried at least one other treatment. T…

This study compares two treatments for women with a common type of early breast cancer (HR+/HER2-). One group gets a targeted drug (ribociclib) plus hormone therapy, while the other gets chemotherapy first, then the same targeted combo. The goal is to see if skipping chemo is saf…

This study observes how well the drug Toripalimab works as a first-line treatment for patients with extensive-stage small cell lung cancer. Researchers will track 1,200 participants in China to measure survival and tumor response in routine clinical practice. The goal is to gathe…

This study will observe 460 adults with diabetes who take semaglutide to see if those with nerve damage are more likely to develop gastric retention (stomach not emptying properly). Participants will be split into two groups based on whether they have neuropathy or not. The goal …

This study enrolls 30 people with metastatic cancer to test a new method that uses RNA from tumor samples to predict where the cancer started. Researchers will analyze the genetic activity of the tumor and use a computer model to identify its tissue of origin. The goal is to impr…

This observational study aims to see if a specific type of immune cell (Tpex) in cancer-free lymph nodes can predict how well PD-1 inhibitors work for people with advanced or recurrent esophageal cancer. Researchers will follow 158 participants to compare survival times based on …

This study tests whether using a transparent cap on the colonoscope during a second look at the lower part of the colon helps doctors find more polyps (adenomas). About 614 adults aged 45 to 75 will be randomly assigned to either a standard second exam or one with the cap. The go…

This study follows 400 adults with advanced HER2-negative breast cancer who have already tried antibody-drug conjugates. Researchers want to see how long patients stay cancer-free or alive after starting eribulin mesylate-based therapy. The study collects past and future treatmen…

This study looks at 100 people who had surgery to remove an infected mesh after hernia repair. It compares removing all the mesh versus only part of it, to see which approach leads to fewer hernia comebacks and infections. The goal is to help doctors choose the best treatment for…

This study tests whether an AI-powered care program can encourage more high-risk adults (ages 40-64) in China to get a colonoscopy, the gold standard for colorectal cancer screening. About 400 participants will be split into two groups: one receives standard care, the other gets …